LOS ANGELES--(BUSINESS WIRE)--DaVinci Biosciences announced today the publication of study results demonstrating the safety and feasibility of its acute and chronic spinal cord injury therapy platform in issue 17(12) of Cell Transplantation, a peer-reviewed journal focused on regenerative medicine. The study demonstrates that administering adult autologous bone marrow derived stem cells via multiple routes is feasible, safe, and most importantly, improves the quality of life for both acute and chronic spinal cord injury (SCI) patients.
